HC Wainwright Has Negative Outlook for ETRA FY2026 Earnings

Electra Therapeutics, Inc. (NASDAQ:ETRA – Free Report) – Investment analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Electra Therapeutics in a report issued on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($5.64) per share for the year, down from their previous forecast of ($3.17). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Electra Therapeutics’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Electra Therapeutics’ Q4 2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($0.68) EPS and FY2027 earnings at ($2.41) EPS.

Several other research analysts have also recently issued reports on the company. Cantor Fitzgerald assumed coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “overweight” rating on the stock. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. JPMorgan Chase & Co. began coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price target for the company. Evercore started coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued a “buy” rating and a $32.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $33.50.

Get Our Latest Stock Report on ETRA

Electra Therapeutics Price Performance

Electra Therapeutics stock opened at $8.94 on Wednesday. Electra Therapeutics has a one year low of $6.86 and a one year high of $15.50. The firm’s fifty day moving average price is $9.47.

Electra Therapeutics (NASDAQ:ETRA – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($3.47) EPS for the quarter, missing the consensus estimate of ($1.76) by ($1.71).

Hedge Funds Weigh In On Electra Therapeutics

Several large investors have recently added to or reduced their stakes in ETRA. RA Capital Management L.P. bought a new position in shares of Electra Therapeutics in the third quarter worth approximately $19,046,000. Logos Global Management LP purchased a new stake in shares of Electra Therapeutics in the third quarter worth $11,250,000. Soleus Capital Management L.P. bought a new stake in shares of Electra Therapeutics during the 3rd quarter valued at $2,812,000. Integral Health Asset Management LLC bought a new stake in shares of Electra Therapeutics during the 3rd quarter valued at $2,250,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Electra Therapeutics during the 3rd quarter valued at $1,465,000.

Insider Transactions at Electra Therapeutics

In related news, Director Orbimed Advisors Llc acquired 1,333,333 shares of the stock in a transaction dated Monday, September 21st. The shares were purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Carl Gordon acquired 1,333,333 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were bought at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the purchase, the director owned 5,126,891 shares in the company, valued at $76,903,365. This trade represents a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 3,796,040 shares of company stock worth $48,699,065.

About Electra Therapeutics

(Get Free Report)

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.

Featured Articles

Earnings History and Estimates for Electra Therapeutics (NASDAQ:ETRA)

Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.